Companies › Ace Cells Lab
3 active drug programs in 3 registered trials: 2 Phase 4, 1 Phase 1; Ophthalmology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ACE Reno Standardized bioactive peptides and amino acids | – | Phase 4 | Hypertensive Nephropathy | Dec 2026 |
| Stem Cells Fortified Eye Drops Stem cell-derived biologic for ocular surface support | – | Phase 4 | Dry Eye | – |
| ACE Retino Peptide-based therapy derived from fetal tissues, mesenchymal stem cells, and bioactive gr | – | Phase 1 | Retinitis Pigmentosa (RP) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06787482 | ACE Retino | Phase 1 | Retinitis Pigmentosa (RP) | Ophthalmology | Jun 2025 |
| NCT07191847 | Stem Cells Fortified Eye Drops | Phase 4 | Dry Eye | Ophthalmology | Dec 2025 |
| NCT07187713 | ACE Reno | Phase 4 | Hypertensive Nephropathy | Genitourinary | Dec 2026 |
No annotated target.
–
Ocugen Laboratoires Thea Beacon Therapeutics Huons Zhaoke (Guangzhou) Ophthalmology Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.